BRCA1 and ovarian cancer: In addition, a recent phase I study evaluating the combination of an Akt inhibitor, AZD5363, plus the PARP inhibitor, olaparib, as a potential strategy for overcoming resistance to PARP inhibition showed responses in a patient with BRCA1-mutant ovarian cancer and also in another with BRCA1/2 wild-type ovarian cancer [105].